What you need to know:

– Zephyr AI, a healthcare know-how firm pioneering explainable AI (XAI) for precision medication, raises $111 million in Sequence A spherical led by Revolution Progress, Eli Lilly & Firm, Jeff Skoll and EPIQ Capital Group.

– The corporate plans to make use of this funding spherical to refine its know-how to strengthen its in depth assortment of coaching and validation datasets, essential for strong AI fashions, ship outcomes even sooner and develop its scientific and business groups.

Democratizing precision medication with next-generation AI

Zephyr AI is a fast-growing healthcare know-how firm centered on revolutionizing precision medication. Their staff of world-class software program engineers and biologists work collectively to leverage large information, superior AI and next-generation know-how to unlock transformational insights within the struggle towards most cancers and cardiometabolic illnesses.

Zephyr AI manages one of many world's most complete healthcare datasets via partnerships and proprietary information sources. Their AI algorithms are particularly designed to deal with the complexity of actual affected person information, a historic problem within the area. In contrast to conventional AI options, Zephyr AI know-how goes past predictions. It supplies the organic context behind the outcomes and supplies essential insights for drug growth and therapy choices.

“The US has the very best variety of preventable deaths from most cancers and cardiometabolic illnesses of any high-income nation. We’ve got to do higher,” stated Grant Verstandig, co-founder and govt chairman of Zephyr AI. “At Zephyr AI, we leverage the ability of AI to achieve new insights to raised outline affected person stratification and response predictions and enhance the federation of real-world information. With our world-class staff and the assist of this investor group, we’re deploying one of many largest scientific genomic datasets, with unprecedented attain throughout illness states and information companions. Collectively, we are actually well-positioned to assist our mission of democratizing precision medication, growing each the pace and success of scientific trials.”